欢迎来到天天文库
浏览记录
ID:33767590
大小:1.78 MB
页数:40页
时间:2019-02-28
《桂泽大黄汤对动脉粥样硬化患者crp、hcy水平的影响》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库。
1、陕西中医学院硕士学位论文桂泽大黄汤对动脉粥样硬化患者CRP、HCY水平的影响姓名:丁惠卿申请学位级别:硕士专业:中医内科学指导教师:王凌201205中文摘要』JllllrllIIfllflIlllflfJlIIIfY215330目的:本文主要通过桂泽大黄汤对中医辨证为气(阳)虚血瘀为主的动脉硬化患者的I临床观察,观察其对动脉粥样硬化性患者CRP、Hcy水平的影响,评价桂泽大黄汤对动脉粥样硬化患者的疗效,为进一步临床治疗及心脑血管病的一、二级预防提供依据。方法:将符合纳入标准的并具有可比性的60例动脉粥样硬化患者随
2、机分为2组,对照组30例予血脂康胶囊、叶酸片治疗。治疗组30例予桂泽大黄汤作为基础方,随症加减,每次200ml,每日2次,早晚分服。2组均30日为1个疗程,观察2组用药后中医证候、CRP及Hcy的变化情况,以评估其临床疗效和安全性。结果:对两组患者性别、年龄、治疗前气(阳)虚血瘀证候积分、CRP及Hcy水平进行统计学分析后无显著差异。治疗后两组比较:治疗组患者的临床症状均较治疗前明显好转,而对照组患者治疗后症状改善不明显,经过组间比较,治疗组与对照组间具有显著差异性(P<0.05);治疗组患者Hcy水平明显降低,
3、而对照组患者Hcy水平降低不显著,经组间比较,两组具有显著差异性(P4、/HCYbytakingAbstractGuizedahuangtangObjective:ToobservetheinfluenceoftheatheroscleroticCRP/HCYontheatheroscleroticwhoareindeficiencyofbloodandqibyusingGuizedahuangtangandtoevaluatethecurativeeffectonthepatientswithatherosclerosiswhoaretreatedbyGuizedahuangtan5、gandtoprovidebasisfortheclinicaltreatmentandtheprimaryandsecondarypreventionofthecardiovascularandcerebrovasculardiseases.Nethods:60patientswithatherosclerosiswhomettheinclusioncriteriaarerandomlydividedintotwogroups.ThecontrolgrouparetreatedbyXuezhikang、Foli6、cacidtablets,andthetreatmentgrouparetreatedbytakingGuizedahuangtangoralIytwiceadayand200mleachtime.Thetwogroupsarebothtreatedinatherapeuticprogramof30days.ThenobservetheTCMsymptomandthechangesoftheCRP/HCYtoassesstheclinicaleffectsandsafety.Result:Beforethetre7、atment,thestatisticalanalysisofthe60patients’sex,age,symptomaticintegralofbloodstasisandthedeficiencyofqi,thelevelofCRPandHCYarenotobviouslydifferent.comparisonofthetwogroupsafterthetreatment:theclinicalsymptomsofthepatientsintreatmentgrouparemuchbetterthanbe8、fore,butthereisnotmuchimprovementamongthepatientsinthecontrolgroup.differencebetweenthetwogroupsisobviouslydifferent(P
4、/HCYbytakingAbstractGuizedahuangtangObjective:ToobservetheinfluenceoftheatheroscleroticCRP/HCYontheatheroscleroticwhoareindeficiencyofbloodandqibyusingGuizedahuangtangandtoevaluatethecurativeeffectonthepatientswithatherosclerosiswhoaretreatedbyGuizedahuangtan
5、gandtoprovidebasisfortheclinicaltreatmentandtheprimaryandsecondarypreventionofthecardiovascularandcerebrovasculardiseases.Nethods:60patientswithatherosclerosiswhomettheinclusioncriteriaarerandomlydividedintotwogroups.ThecontrolgrouparetreatedbyXuezhikang、Foli
6、cacidtablets,andthetreatmentgrouparetreatedbytakingGuizedahuangtangoralIytwiceadayand200mleachtime.Thetwogroupsarebothtreatedinatherapeuticprogramof30days.ThenobservetheTCMsymptomandthechangesoftheCRP/HCYtoassesstheclinicaleffectsandsafety.Result:Beforethetre
7、atment,thestatisticalanalysisofthe60patients’sex,age,symptomaticintegralofbloodstasisandthedeficiencyofqi,thelevelofCRPandHCYarenotobviouslydifferent.comparisonofthetwogroupsafterthetreatment:theclinicalsymptomsofthepatientsintreatmentgrouparemuchbetterthanbe
8、fore,butthereisnotmuchimprovementamongthepatientsinthecontrolgroup.differencebetweenthetwogroupsisobviouslydifferent(P
此文档下载收益归作者所有